JP2001519787A - 膀胱内ドラッグデリバリーシステム - Google Patents

膀胱内ドラッグデリバリーシステム

Info

Publication number
JP2001519787A
JP2001519787A JP54197098A JP54197098A JP2001519787A JP 2001519787 A JP2001519787 A JP 2001519787A JP 54197098 A JP54197098 A JP 54197098A JP 54197098 A JP54197098 A JP 54197098A JP 2001519787 A JP2001519787 A JP 2001519787A
Authority
JP
Japan
Prior art keywords
formulation
active ingredient
bladder
preparation
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54197098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001519787A5 (enExample
Inventor
トーマス ビー オットーボニ
ロナルド ケイ ヤマモト
スタンリー アール コンスタン
Original Assignee
ポイント バイオメディカル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポイント バイオメディカル コーポレイション filed Critical ポイント バイオメディカル コーポレイション
Publication of JP2001519787A publication Critical patent/JP2001519787A/ja
Publication of JP2001519787A5 publication Critical patent/JP2001519787A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP54197098A 1997-04-03 1998-04-02 膀胱内ドラッグデリバリーシステム Ceased JP2001519787A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83324797A 1997-04-03 1997-04-03
US08/833,247 1997-04-03
PCT/US1998/006445 WO1998043555A1 (en) 1997-04-03 1998-04-02 Intravesical drug delivery system

Publications (2)

Publication Number Publication Date
JP2001519787A true JP2001519787A (ja) 2001-10-23
JP2001519787A5 JP2001519787A5 (enExample) 2005-11-24

Family

ID=25263865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54197098A Ceased JP2001519787A (ja) 1997-04-03 1998-04-02 膀胱内ドラッグデリバリーシステム

Country Status (10)

Country Link
US (3) US6039967A (enExample)
EP (1) EP0971641A4 (enExample)
JP (1) JP2001519787A (enExample)
KR (1) KR20010006027A (enExample)
AU (1) AU6876498A (enExample)
CA (1) CA2285591A1 (enExample)
DE (1) DE19882286T1 (enExample)
GB (1) GB2338414B (enExample)
NO (1) NO994837L (enExample)
WO (1) WO1998043555A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013851A1 (ja) * 2004-08-03 2006-02-09 Nippon Shinyaku Co., Ltd. 体孔内用デバイス及び持続性製剤
JP2006506385A (ja) * 2002-10-22 2006-02-23 ザ バイオメリックス コーポレーション 治療剤を小嚢内デリバリーするための方法およびシステム
JP2009504271A (ja) * 2005-08-11 2009-02-05 マサチューセッツ・インスティテュート・オブ・テクノロジー 膀胱内薬物送達デバイスおよび方法
JP2022531163A (ja) * 2019-04-30 2022-07-06 トリゴン ファーマ リミテッド 膀胱への薬剤滴下投与用の製剤および方法と、膀胱疾患の治療

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6419935B1 (en) * 1998-07-30 2002-07-16 L'oreal S.A. Cosmetic skin treatment method and cleansing treatment patch
US6293923B1 (en) 1999-03-15 2001-09-25 Innoventions, Inc. Intravesicular balloon
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1949890A3 (en) * 1999-06-04 2011-05-18 ALZA Corporation Implantable gel compositions and method of manufacture
AU779277B2 (en) * 1999-06-04 2005-01-13 Alza Corporation Implantable gel compositions and method of manufacture
US6740039B1 (en) 1999-08-20 2004-05-25 Koninklijke Philips Electronics N.V. Methods and apparatus for displaying information relating to delivery and activation of a therapeutic agent using ultrasound energy
US6527718B1 (en) 1999-08-20 2003-03-04 Brian G Connor Ultrasound system for continuous imaging and delivery of an encapsulated agent
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
MXPA02010542A (es) * 2000-04-26 2003-10-14 Watson Pharmaceuticals Inc Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina.
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US6398718B1 (en) 2000-06-15 2002-06-04 Innoventions, Inc. Intravesicular device
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
US6699665B1 (en) * 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
WO2002071922A2 (en) * 2001-03-13 2002-09-19 Clemson University Intraurethral device for treating or detecting various diseases or infections of the urinary system
US6558312B2 (en) 2001-03-13 2003-05-06 Clemson University Intraurethral device for incontinence
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
US6702744B2 (en) * 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US6893431B2 (en) 2001-10-15 2005-05-17 Scimed Life Systems, Inc. Medical device for delivering patches
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
JP4317452B2 (ja) 2001-11-01 2009-08-19 スペクトラム・ファーマシューティカルス・インコーポレーテッド 膀胱癌の膀胱内処置用の医学的組成物
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US7149874B2 (en) * 2002-08-16 2006-12-12 Micron Technology, Inc. Memory hub bypass circuit and method
US7597903B2 (en) * 2002-12-02 2009-10-06 Shenkar College Of Engineering And Design Method and composition for producing catheters with antibacterial property
AU2003286129A1 (en) * 2002-12-11 2004-06-30 Coloplast A/S A urinary catheter device with a pharmaceutically active composition
JP2004246317A (ja) * 2002-12-20 2004-09-02 Hitachi Ltd 冷陰極型フラットパネルディスプレイ
EP3103422A1 (en) 2003-03-14 2016-12-14 Intersect ENT, Inc. Sinus delivery of sustained release therapeutics
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
AU2004241111B2 (en) 2003-05-15 2010-05-27 Dsm Ip Assets B.V Manufacture and use of implantable reticulated elastomeric matrices
US20040249364A1 (en) * 2003-06-03 2004-12-09 Ilya Kaploun Device and method for dispensing medication to tissue lining a body cavity
CA2533165A1 (en) * 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
NZ528648A (en) 2003-10-02 2005-08-26 Agres Ltd Altering animal waste composition
US20050175709A1 (en) 2003-12-11 2005-08-11 Baty Ace M.Iii Therapeutic microparticles
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
US7854944B2 (en) 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
WO2006107957A2 (en) 2005-04-04 2006-10-12 Sinexus, Inc. Device and methods for treating paranasal sinus conditions
US8303972B2 (en) * 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8187621B2 (en) * 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9346029B2 (en) 2005-06-06 2016-05-24 The University Of British Columbia Polymer-based serum albumin substitute
US7732190B2 (en) * 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
WO2008035172A2 (en) * 2006-09-18 2008-03-27 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing desmopressin
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) * 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US20080161639A1 (en) * 2006-12-28 2008-07-03 Olympus Medical Systems Corporation Capsule medical apparatus and body-cavity observation method
US8702591B2 (en) * 2007-01-12 2014-04-22 Olympus Medical Systems Corp. Capsule medical apparatus
DE102007003765A1 (de) * 2007-01-19 2008-07-24 Farco-Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von Inkontinenz
MX348005B (es) 2007-12-11 2017-05-23 Massachusetts Inst Technology Dispositivo implantable de liberación de fármacos y métodos para tratar la vejiga y otras vesículas o lúmenes corporales.
US20090198179A1 (en) 2007-12-18 2009-08-06 Abbate Anthony J Delivery devices and methods
EP2320832A4 (en) 2008-08-01 2015-07-29 Intersect Ent Inc METHODS AND DEVICES FOR CRIMPING SELF-DILATABLE DEVICES
CA2733468C (en) * 2008-08-09 2017-12-05 Massachusetts Institute Of Technology Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
WO2010129331A2 (en) * 2009-04-28 2010-11-11 Ams Research Corporation Biologic treatment system and method
CA3031836A1 (en) 2009-05-05 2010-11-11 Board Of Regents, The University Of Texas System Formulations of volatile anesthetics for reducing inflammation
CN102573981B (zh) 2009-05-15 2016-06-22 因特尔赛克特耳鼻喉公司 可展开装置及其使用方法
CN101724163B (zh) * 2009-06-23 2011-09-07 河南科技大学 一种壳聚糖衍生物复合微球及其制备方法和应用
JP5913095B2 (ja) 2009-06-26 2016-04-27 タリス バイオメディカル エルエルシー 植込み型薬物送達装置及びその作製方法
DE102009035586A1 (de) 2009-07-31 2011-02-03 Fresenius Kabi Deutschland Gmbh Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
EP3884988B1 (en) * 2009-12-17 2025-06-18 TARIS Biomedical LLC Implantable device with intravesical tolerability
AU2015201123B2 (en) * 2009-12-17 2016-04-21 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
EP2525777B1 (en) 2010-01-20 2019-05-29 UroGen Pharma Ltd. Material and method for treating internal cavities
CA2999629C (en) 2010-03-01 2020-12-15 The University Of British Columbia Derivatized hyperbranched polyglycerols
WO2012018923A1 (en) 2010-08-05 2012-02-09 Taris Biomedical, Inc. Implantable drug delivery devices for genitourinary sites
US8690840B2 (en) 2010-10-06 2014-04-08 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
AU2012205654B2 (en) 2011-01-10 2016-09-08 Allergan, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
CA2825399A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
EP2734187B1 (en) 2011-07-20 2018-09-05 UroGen Pharma Ltd. Materials and method for treating internal body cavities
ES2596215T3 (es) 2011-10-24 2017-01-05 Asana Biosciences, Llc Ciclohexilaminas
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
CN112169134B (zh) 2012-05-19 2022-11-29 塔里斯生物医药公司 具有改良取回特征的可植入泌尿器械
US10406332B2 (en) 2013-03-14 2019-09-10 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
JP6517186B2 (ja) 2013-03-15 2019-05-22 タリス バイオメディカル エルエルシー 薬物透過性構成部材を備えた薬物送達デバイス、及び方法
CA2919215C (en) 2013-08-19 2022-11-29 Taris Biomedical Llc Multi-unit drug delivery devices and methods
WO2015095128A1 (en) 2013-12-16 2015-06-25 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
CN103861091B (zh) * 2014-03-20 2016-04-27 辽宁亿灵科创生物医药科技有限公司 治疗膀胱炎的药物组合物
JP6856380B2 (ja) 2014-06-26 2021-04-07 タリス バイオメディカル エルエルシー 弾性ポリマー−薬物マトリックス系を含む膀胱内薬物送達デバイス及び方法
CZ308594B6 (cs) * 2014-09-29 2020-12-23 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Mukoadhezivní nosiče částic, způsob přípravy a použití
CA2974376A1 (en) 2015-01-22 2016-07-28 Intersect Ent, Inc. Drug-coated balloon
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
EP3528813B1 (en) 2016-09-30 2025-04-16 ABS Development 1, Inc. P2x3 and/or p2x2/3 compounds and methods
US20180256867A1 (en) * 2017-03-07 2018-09-13 Bruce H. Levin Nasal Delivery Device and Methods of Use
IT201700104446A1 (it) 2017-09-19 2019-03-19 Lo Li Pharma Srl Compositions, uses and methods for treatment of infertility and subfertility
ES2981316T3 (es) 2017-12-22 2024-10-08 Lo Li Pharma Srl Tratamiento de fibrosis con inositol
WO2020069376A1 (en) * 2018-09-27 2020-04-02 Watershed Medical, Inc. Device and method for treating infections
WO2020168244A1 (en) 2019-02-15 2020-08-20 Incelldx, Inc. Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
IT201900003843A1 (it) 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
ES2947713T3 (es) 2019-06-13 2023-08-17 Hollister Inc Productos de catéter urinario reutilizables
WO2020263859A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
US20210100950A1 (en) * 2019-10-02 2021-04-08 Watershed Medical, Inc. Device and method for improving retention of a therapy in the bladder
KR20250002365A (ko) * 2022-04-19 2025-01-07 워터셰드 메디칼 인코포레이티드 비뇨계 질환 치료를 위한 제형(formulation for treating urinary system disorders)
IT202200013867A1 (it) 2022-06-30 2023-12-30 Lo Li Pharma Srl Composizione per il trattamento dell’ infezione da papilloma virus (hpv)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2961374A (en) * 1950-10-14 1960-11-22 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
JPS51140582A (en) * 1975-05-30 1976-12-03 Nec Corp Semiconductor resistance element
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4871542A (en) * 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
FR2657018A1 (fr) * 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
WO1991017745A1 (en) * 1990-05-23 1991-11-28 Southwest Research Institute Filament system for delivering a medicament and method
DE69329407T2 (de) * 1992-06-02 2001-05-03 Bard Inc C R Verfahren und Implantatvorrichtung für Langzeitwirkstoffabgabe

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506385A (ja) * 2002-10-22 2006-02-23 ザ バイオメリックス コーポレーション 治療剤を小嚢内デリバリーするための方法およびシステム
WO2006013851A1 (ja) * 2004-08-03 2006-02-09 Nippon Shinyaku Co., Ltd. 体孔内用デバイス及び持続性製剤
JP2009504271A (ja) * 2005-08-11 2009-02-05 マサチューセッツ・インスティテュート・オブ・テクノロジー 膀胱内薬物送達デバイスおよび方法
JP2022531163A (ja) * 2019-04-30 2022-07-06 トリゴン ファーマ リミテッド 膀胱への薬剤滴下投与用の製剤および方法と、膀胱疾患の治療
JP7350372B2 (ja) 2019-04-30 2023-09-26 トリゴン ファーマ リミテッド 膀胱への薬剤滴下投与用の製剤および方法と、膀胱疾患の治療

Also Published As

Publication number Publication date
GB9923410D0 (en) 1999-12-08
US6524608B2 (en) 2003-02-25
NO994837D0 (no) 1999-10-04
CA2285591A1 (en) 1998-10-08
DE19882286T1 (de) 2000-04-27
US6039967A (en) 2000-03-21
GB2338414A (en) 1999-12-22
GB2338414B (en) 2001-12-19
EP0971641A1 (en) 2000-01-19
AU6876498A (en) 1998-10-22
KR20010006027A (ko) 2001-01-15
NO994837L (no) 1999-11-10
US6207180B1 (en) 2001-03-27
US20010019719A1 (en) 2001-09-06
WO1998043555A1 (en) 1998-10-08
EP0971641A4 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
JP2001519787A (ja) 膀胱内ドラッグデリバリーシステム
AU762677B2 (en) Prolonged release bioadhesive vaginal gel dosage form
EP1263416B1 (en) Compressed microparticles for dry injection
JP3941878B2 (ja) 生物分解性放出制御溶融紡糸デリバリーシステム
JP3208568B2 (ja) 眼用の医薬製剤およびその製造方法
US6488952B1 (en) Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
JPH10502673A (ja) 持続性の局所麻酔を施すための製剤および方法
JP2001504439A (ja) 局所投与型生分解性徐放型歯周炎用薬剤組成物及びその製造方法
JP2009509982A (ja) 内耳疾患を治療するための医薬品組成物
WO1989009066A1 (en) Controlled release composition
JP2002521347A (ja) 陰イオン多糖を含む徐放製剤
DE212011100034U1 (de) Material zur Behandlung von inneren Hohlräumen
JPH07179361A (ja) 歯周病処置用複合物質
JP2001515456A (ja) 口腔の苦痛状態を治療するための経口投与および方法
JP2002524494A (ja) 一時的および空間的制御を供する経口で投与された制御薬剤送出系
JPWO2007102447A1 (ja) 付着型マイクロカプセル
EP3222270A1 (en) Compositions for mucosal adhesion and uses thereof
CN100534527C (zh) 用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
CN118697697B (zh) 一种脂质体封装的长效罗哌卡因缓释系统
JP2025102634A (ja) 避妊マイクロニードル用微粒球組成物及びそれを含む避妊マイクロニードル
Sheu Chia-Yu Su1, Hsiu-O Ho1, Ying-Chen Chen1, Yu-Ting Yu1, Der-Zen Liu2, Fang-Ching Chao1 &
Samad et al. 20 Microsphere
CN104288844A (zh) 具有可控堆积密度的可生物降解植入物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090309

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090427

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090804